Last reviewed · How we verify
NCT00652782
A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of The Effects of MK7418, Both as Monotherapy and in Combination With Furosemide, On Diuresis and Renal Function in Patients With Congestive Heart Failure (CHF) And Renal Impairment Treated With Oral Loop Diuretics Who Require Hospitalization For Fluid Overload
Phase 2 trial testing rolofyline in Congestive Heart Failure in 160 participants. Completed.
1 August 2005
Quick facts
| Lead sponsor | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 1 December 2004 |
| Primary completion | 1 August 2005 |
Drugs / interventions tested
- rolofyline — full drug profile →
- Comparator Placebo (unspecified)
Conditions studied
- Congestive Heart Failure — all drugs for Congestive Heart Failure →
- Renal Impairment — all drugs for Renal Impairment →
Sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →
Who can join
18 and older, any sex, with Congestive Heart Failure or Renal Impairment. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To measure the diuretic effect of a single dose of the study medication (monotherapy) over six hours compared to a single dose of IV placebo (monotherapy) in CHF patients with renal impairment
Time frame: 30 days
Sponsor's own description
A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00652782
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Congestive Heart Failure
Currently open trials in the same condition.
- NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
- NCT06526884 — Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC) · NA · active not recruiting
- NCT06495892 — PVP-Guided Decongestive Therapy in HF 2 · Phase 4 · recruiting
- NCT06374277 — Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence · NA · recruiting
- NCT05971225 — Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00652782 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Last refreshed: 1 April 2008
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00652782.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing